{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:54:45Z","timestamp":1774709685127,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Optic pathway gliomas (OPGs), also known as Visual Pathway Gliomas, are insidious, debilitating tumours. They are most commonly WHO grade 1 pilocytic astrocytomas and frequently occur in patients with neurofibromatosis type 1. The location of OPGs within the optic pathway typically precludes complete resection or optimal radiation dosing, hence outcomes remain poor compared to many other low-grade gliomas. The aim of this systematic review was to formulate a comprehensive list of all current ongoing clinical trials that are specifically looking at clinical care of OPGs in order to identify trends in current research and provide an overview to guide future research efforts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The Cochrane Controlled Register of Trials (CENTRAL) and ClinicalTrials.gov were searched. Inclusion and exclusion criteria were applied and final results were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>501 clinical trials were identified with the search strategy. All were screened and eligible studies extracted and reviewed. This yielded 36 ongoing clinical trials, 27 of which were pharmacological agents in phase I-III. The remaining trials were a mixture of biological agents, radiation optimisation, diagnostic imaging, surgical intervention, and a social function analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>OPG is a complex multifaceted disease, and advances in care require ongoing research efforts across a spectrum of different research fields. This review provides an update on the current state of research in OPG and summarises ongoing trials.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00381-020-04724-1","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:02:26Z","timestamp":1592438546000},"page":"1869-1886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A systematic review of ongoing clinical trials in optic pathway gliomas"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4488-4034","authenticated-orcid":false,"given":"Ciaran Scott","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Castro","family":"Devesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Ince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Aquilina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"4724_CR1","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/FOC-07\/11\/E2","volume":"23","author":"MJ Binning","year":"2007","unstructured":"Binning MJ, Liu JK, Kestle JRW, Brockmeyer DL, Walker ML (2007) Optic pathway gliomas: a review. Neurosurg Focus 23:E2","journal-title":"Neurosurg Focus"},{"key":"4724_CR2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","volume":"104","author":"J Helfferich","year":"2016","unstructured":"Helfferich J, Nijmeijer R, Brouwer OF et al (2016) Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 104:30\u201341","journal-title":"Crit Rev Oncol Hematol"},{"key":"4724_CR3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00381-015-2855-7","volume":"31","author":"K Aquilina","year":"2015","unstructured":"Aquilina K, Daniels DJ, Spoudeas H, Phipps K, Gan HW, Boop FA (2015) Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions. Childs Nerv Syst 31:2041\u20132049","journal-title":"Childs Nerv Syst"},{"key":"4724_CR4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11940-014-0333-2","volume":"17","author":"RP Thomas","year":"2015","unstructured":"Thomas RP, Gibbs IC, Xu LW et al (2015) Treatment options for optic pathway gliomas. Curr Treat Options Neurol 17:333","journal-title":"Curr Treat Options Neurol"},{"key":"4724_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00381-018-3904-9","volume":"35","author":"NC Calixto","year":"2019","unstructured":"Calixto NC, Sim\u00e3o GN, Dos Santos AC et al (2019) Monitoring optic chiasmatic-hypothalamic glioma volumetric changes by MRI in children under clinical surveillance or chemotherapy. Childs Nerv Syst 35:63\u201372","journal-title":"Childs Nerv Syst"},{"key":"4724_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2011.10.067","volume":"84","author":"RM Awdeh","year":"2012","unstructured":"Awdeh RM, Kiehna EN, Drewry RD, Kerr NC, Haik BG, Wu S, Xiong X, Merchant TE (2012) Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys 84:46\u201351","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4724_CR7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2017.07.023","volume":"99","author":"DS Tsang","year":"2017","unstructured":"Tsang DS, Murphy ES, Merchant TE (2017) Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys 99:642\u2013651","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4724_CR8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1215\/15228517-2008-033","volume":"10","author":"Y Sawamura","year":"2008","unstructured":"Sawamura Y, Kamada K, Kamoshima Y, Yamaguchi S, Tajima T, Tsubaki J, Fujimaki T (2008) Role of surgery for optic pathway\/hypothalamic astrocytomas in children. Neuro-Oncology 10:725\u2013733","journal-title":"Neuro-Oncology"},{"key":"4724_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2013.8.PEDS12546","volume":"13","author":"J Goodden","year":"2014","unstructured":"Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, Thorp N, Mallucci C (2014) The role of surgery in optic pathway\/hypothalamic gliomas in children. J Neurosurg Pediatr 13:1\u201312","journal-title":"J Neurosurg Pediatr"},{"key":"4724_CR10","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1210\/jc.2015-2028","volume":"100","author":"H-W Gan","year":"2015","unstructured":"Gan H-W, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA (2015) Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab 100:3787\u20133799","journal-title":"J Clin Endocrinol Metab"},{"key":"4724_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2017.06.019","volume":"75","author":"V Robert-Boire","year":"2017","unstructured":"Robert-Boire V, Rosca L, Samson Y, Ospina LH, Perreault S (2017) Clinical presentation and outcome of patients with optic pathway glioma. Pediatr Neurol 75:55\u201360","journal-title":"Pediatr Neurol"},{"key":"4724_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICU.0000000000000370","volume":"28","author":"N Rasool","year":"2017","unstructured":"Rasool N, Odel JG, Kazim M (2017) Optic pathway glioma of childhood. Curr Opin Ophthalmol 28:289\u2013295","journal-title":"Curr Opin Ophthalmol"},{"key":"4724_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29327\/apn.v1i1(September-December).2","volume":"1","author":"ET Hidalgo","year":"2019","unstructured":"Hidalgo ET, Kvint S, Orillac C et al (2019) Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic\/pilomyxoid optic pathway gliomas. J Neurosurg Pediatr 1:1\u20138","journal-title":"J Neurosurg Pediatr"},{"key":"4724_CR14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12957-019-1686-5","volume":"17","author":"L Y-y","year":"2019","unstructured":"Y-y L, Y-t L, Hu Q-l et al (2019) Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis. World J Surg Oncol 17:152","journal-title":"World J Surg Oncol"},{"issue":"11","key":"4724_CR15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/cancers11111772","volume":"11","author":"M Taddei","year":"2019","unstructured":"Taddei M, Erbetta A, Esposito S et al (2019) Brain tumors in NF1 children: influence on neurocognitive and behavioral outcome. Cancers (Basel) 11(11):1772","journal-title":"Cancers (Basel)"},{"key":"4724_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"C Papini","year":"2020","unstructured":"Papini C, Dineen RA, Walker DA et al (2020) Neuropsychological outcomes of children with optic pathway glioma. Sci Rep 10:1\u201310","journal-title":"Sci Rep"},{"key":"4724_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"4724_CR18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473","journal-title":"Ann Intern Med"},{"key":"4724_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00381-015-2987-9","volume":"32","author":"MS Zaghloul","year":"2016","unstructured":"Zaghloul MS (2016) Single pediatric neuro-oncology center may make difference in low\/middle-income countries. Childs Nerv Syst 32:241\u2013242","journal-title":"Childs Nerv Syst"},{"key":"4724_CR20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00381-015-2771-x","volume":"31","author":"MH Chan","year":"2015","unstructured":"Chan MH, Boop F, Qaddoumi I (2015) Challenges and opportunities to advance pediatric neuro-oncology care in the developing world. Childs Nerv Syst 31:1227\u20131237","journal-title":"Childs Nerv Syst"},{"key":"4724_CR21","doi-asserted-by":"crossref","first-page":"e26737","DOI":"10.1002\/pbc.26737","volume":"64","author":"L Hessissen","year":"2017","unstructured":"Hessissen L, Parkes J, Amayiri N, Mushtaq N, Sirachainan N, Anacak Y, Mitra D, Figaji A, Schouten-van Meeteren A, Sullivan M, Burger H, Davidson A, Bouffet E, Bailey S (2017) SIOP PODC adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatr Blood Cancer 64:e26737","journal-title":"Pediatr Blood Cancer"},{"key":"4724_CR22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","volume":"61","author":"R Listernick","year":"2007","unstructured":"Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189\u2013198","journal-title":"Ann Neurol"},{"key":"4724_CR23","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/FOC-07\/11\/E3","volume":"23","author":"MF Shamji","year":"2007","unstructured":"Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3","journal-title":"Neurosurg Focus"},{"issue":"Suppl 1","key":"4724_CR24","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","volume":"37","author":"PMK de Blank","year":"2017","unstructured":"de Blank PMK, Fisher MJ, Liu GT et al (2017) Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol 37(Suppl 1):S23\u2013S32","journal-title":"J Neuroophthalmol"},{"key":"4724_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000028680","volume":"29","author":"M-Y Chan","year":"1998","unstructured":"Chan M-Y, Foong AP, Heisey DM, Harkness W, Hayward R, Michalski A (1998) Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis. Pediatr Neurosurg 29:23\u201328","journal-title":"Pediatr Neurosurg"},{"key":"4724_CR26","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","volume":"21","author":"V Laithier","year":"2003","unstructured":"Laithier V, Grill J, Le Deley M-C et al (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572\u20134578","journal-title":"J Clin Oncol"},{"key":"4724_CR27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT (2018) First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov 8:184\u2013195","journal-title":"Cancer Discov"},{"key":"4724_CR28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/cancers11091262","volume":"11","author":"KC Schreck","year":"2019","unstructured":"Schreck KC, Grossman SA, Pratilas CA (2019) BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers 11:1262","journal-title":"Cancers"},{"key":"4724_CR29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","volume":"78","author":"JN Sanchez","year":"2018","unstructured":"Sanchez JN, Wang T, Cohen MS (2018) BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 78:549\u2013566","journal-title":"Drugs."},{"key":"4724_CR30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fonc.2018.00526","volume":"8","author":"F Del Bufalo","year":"2018","unstructured":"Del Bufalo F, Ceglie G, Cacchione A et al (2018) BRAF V600E inhibitor (Vemurafenib) for BRAF V600E mutated low grade gliomas. Front Oncol 8:526","journal-title":"Front Oncol"},{"key":"4724_CR31","doi-asserted-by":"crossref","first-page":"i110","DOI":"10.1093\/neuonc\/noy059.367","volume":"20","author":"JD Wright","year":"2018","unstructured":"Wright JD, Zimmerman MA, Fine E, Aspri T et al (2018) Type 2 II BRAF inhibitor TAK-580 shows promise for upcoming clinical trial as evidenced by single patient IND study. Neuro-oncology 20:i110","journal-title":"Neuro-oncology"},{"key":"4724_CR32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/neuonc\/nou329","volume":"17","author":"A Kaul","year":"2015","unstructured":"Kaul A, Toonen JA, Cimino PJ, Gianino SM, Gutmann DH (2015) Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro-Oncology 17:843\u2013853","journal-title":"Neuro-Oncology"},{"key":"4724_CR33","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ et al (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375:2550\u20132560","journal-title":"N Engl J Med"},{"key":"4724_CR34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011\u20131022","journal-title":"Lancet Oncol"},{"key":"4724_CR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","volume":"132","author":"RA Avery","year":"2014","unstructured":"Avery RA, Hwang EI, Jakacki RI, Packer RJ (2014) Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 132:111\u2013114","journal-title":"JAMA Ophthalmol"},{"key":"4724_CR36","first-page":"1193","volume":"21","author":"WS Wu","year":"2019","unstructured":"Wu WS, Liu JJ, Sun YL et al (2019) Effect of bevacizumab in treatment of children with optic pathway glioma. Zhongguo Dang Dai Er Ke Za Zhi 21:1193","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"4724_CR37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cam4.1799","volume":"8","author":"N Zhukova","year":"2019","unstructured":"Zhukova N, Rajagopal R, Lam A, Coleman L, Shipman P, Walwyn T, Williams M, Sullivan M, Campbell M, Bhatia K, Gottardo NG, Hansford JR (2019) Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Med 8:40\u201350","journal-title":"Cancer Med"},{"key":"4724_CR38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00381-019-04407-6","volume":"36","author":"F Yamasaki","year":"2020","unstructured":"Yamasaki F, Takano M, Yonezawa U, Taguchi A, Kolakshyapati M, Okumichi H, Kiuchi Y, Kurisu K (2020) Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review. Childs Nerv Syst 36:635\u2013639","journal-title":"Childs Nerv Syst"},{"key":"4724_CR39","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A et al (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860","journal-title":"Cancer Manag Res"},{"key":"4724_CR40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/ctrv.2000.0188","volume":"26","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26:351\u2013362","journal-title":"Cancer Treat Rev"},{"key":"4724_CR41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000368903","volume":"88","author":"MR Hassler","year":"2015","unstructured":"Hassler MR, Sax C, Flechl B, Ackerl M, Preusser M, Hainfellner JA, Woehrer A, Dieckmann KU, R\u00f6ssler K, Prayer D, Marosi C (2015) Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. Oncology 88:173\u2013179","journal-title":"Oncology"},{"key":"4724_CR42","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1158\/1078-0432.CCR-07-1546","volume":"13","author":"HA Fine","year":"2007","unstructured":"Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13:7101\u20137106","journal-title":"Clin Cancer Res"},{"key":"4724_CR43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2008.03.046","volume":"73","author":"J Drappatz","year":"2009","unstructured":"Drappatz J, Wong ET, Schiff D et al (2009) A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:222\u2013227","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4724_CR44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","volume":"29","author":"KE Warren","year":"2011","unstructured":"Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, MacDonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29:324\u2013329","journal-title":"J Clin Oncol"},{"key":"4724_CR45","first-page":"17","volume":"22","author":"CA Moore","year":"2018","unstructured":"Moore CA, Ibrahim M, Kapila A et al (2018) Glioblastoma multiforme in a patient with multiple myeloma: a case report and literature review. Perm J 22:17\u2013125","journal-title":"Perm J"},{"key":"4724_CR46","doi-asserted-by":"crossref","unstructured":"Fangusaro JR, Locatelli F, Garr\u00e9 ML et al (2019) A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors","DOI":"10.1200\/JCO.2019.37.15_suppl.10035"},{"key":"4724_CR47","first-page":"2963","volume":"8","author":"T Mukhopadhyay","year":"2002","unstructured":"Mukhopadhyay T, Sasaki J, Ramesh R et al (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 8:2963\u20132969","journal-title":"Clin Cancer Res"},{"key":"4724_CR48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology 13:974\u2013982","journal-title":"Neuro-Oncology"},{"key":"4724_CR49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/nop\/npv041","volume":"3","author":"B Purow","year":"2016","unstructured":"Purow B (2016) Repurposing existing agents as adjunct therapies for glioblastoma. Neuro-Oncol Pract 3:154\u2013163","journal-title":"Neuro-Oncol Pract"},{"issue":"9","key":"4724_CR50","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/cancers11091284","volume":"11","author":"AE Guerini","year":"2019","unstructured":"Guerini AE, Triggiani L, Maddalo M et al (2019) Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel) 11(9):1284","journal-title":"Cancers (Basel)"},{"key":"4724_CR51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1535-7163.MCT-05-0533","volume":"5","author":"IY Ey\u00fcpoglu","year":"2006","unstructured":"Ey\u00fcpoglu IY, Hahnen E, Tr\u00e4nkle C, Savaskan NE, Siebzehnr\u00fcbl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Bl\u00fcmcke I (2006) Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 5:1248\u20131255","journal-title":"Mol Cancer Ther"},{"key":"4724_CR52","first-page":"615","volume":"35","author":"P Lee","year":"2015","unstructured":"Lee P, Murphy B, Miller R et al (2015) Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res 35:615\u2013625","journal-title":"Anticancer Res"},{"key":"4724_CR53","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/cncr.26659","volume":"118","author":"K Warren","year":"2012","unstructured":"Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, Shih J, Camphausen K (2012) A phase 2 study of pegylated interferon \u03b1-2b (PEG-Intron\u00ae) in children with diffuse intrinsic pontine glioma. Cancer 118:3607\u20133613","journal-title":"Cancer"},{"key":"4724_CR54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40268-017-0180-1","volume":"17","author":"D Lubanska","year":"2017","unstructured":"Lubanska D, Porter L (2017) Revisiting CDK inhibitors for treatment of glioblastoma multiforme. Drugs R D 17:255\u2013263","journal-title":"Drugs R D"},{"key":"4724_CR55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fonc.2018.00335","volume":"8","author":"P Weyerh\u00e4user","year":"2018","unstructured":"Weyerh\u00e4user P, Kantelhardt SR, Kim EL (2018) Re-purposing chloroquine for glioblastoma: potential merits and confounding variables. Front Oncol 8:335","journal-title":"Front Oncol"},{"key":"4724_CR56","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801\u20131811","journal-title":"N Engl J Med"},{"key":"4724_CR57","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"JP MacKeigan","year":"2015","unstructured":"MacKeigan JP, Krueger DA (2015) Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro-Oncology 17:1550\u20131559","journal-title":"Neuro-Oncology"},{"key":"4724_CR58","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","volume":"24","author":"C Kyi","year":"2018","unstructured":"Kyi C, Roudko V, Sabado R et al (2018) Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. Clin Cancer Res 24:4937\u20134948","journal-title":"Clin Cancer Res"},{"key":"4724_CR59","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","volume":"103","author":"G Fulci","year":"2006","unstructured":"Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA (2006) Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103:12873\u201312878","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4724_CR60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-006-9147-8","volume":"79","author":"JE Wolff","year":"2006","unstructured":"Wolff JE, Wagner S, Reinert C et al (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neuro-Oncol 79:315\u2013321","journal-title":"J Neuro-Oncol"},{"key":"4724_CR61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2019.11.025","volume":"470","author":"B Du","year":"2020","unstructured":"Du B, Waxman DJ (2020) Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett 470:170\u2013180","journal-title":"Cancer Lett"},{"key":"4724_CR62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/noy146","volume":"21","author":"AS Yamashita","year":"2019","unstructured":"Yamashita AS, da Costa RM, Borodovsky A et al (2019) Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-Oncology 21:189\u2013200","journal-title":"Neuro-Oncology"},{"issue":"505","key":"4724_CR63","doi-asserted-by":"crossref","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca EA, Yu JS, Lukas RV et al (2019) Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med 11(505):eaaw5680","journal-title":"Sci Transl Med"},{"key":"4724_CR64","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A et al (2019) CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 25:2560\u20132574","journal-title":"Clin Cancer Res"},{"key":"4724_CR65","doi-asserted-by":"crossref","first-page":"1684127","DOI":"10.1080\/2162402X.2019.1684127","volume":"9","author":"B Huang","year":"2020","unstructured":"Huang B, Luo L, Wang J, He B, Feng R, Xian N, Zhang Q, Chen L, Huang G (2020) B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Oncoimmunology 9:1684127","journal-title":"Oncoimmunology"},{"key":"4724_CR66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40644-019-0250-4","volume":"19","author":"U Salem","year":"2019","unstructured":"Salem U, Kumar VA, Madewell JE, Schomer DF, de Almeida Bastos DC, Zinn PO, Weinberg JS, Rao G, Prabhu SS, Colen RR (2019) Neurosurgical applications of MRI guided laser interstitial thermal therapy (LITT). Cancer Imaging 19:65","journal-title":"Cancer Imaging"},{"key":"4724_CR67","doi-asserted-by":"crossref","first-page":"14184","DOI":"10.1038\/s41598-019-50738-4","volume":"9","author":"L Shen","year":"2019","unstructured":"Shen L, Zhang J, Lee H, Batista MT, Johnston SA (2019) RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines. Sci Rep 9:14184","journal-title":"Sci Rep"},{"key":"4724_CR68","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/mrm.25347","volume":"73","author":"B Bilgic","year":"2015","unstructured":"Bilgic B, Gagoski BA, Cauley SF et al (2015) Wave-CAIPI for highly accelerated 3D imaging. Magn Reson Med 73:2152\u20132162","journal-title":"Magn Reson Med"},{"key":"4724_CR69","first-page":"2073","volume":"40","author":"J Conklin","year":"2019","unstructured":"Conklin J, Longo MGF, Cauley SF et al (2019) Validation of highly accelerated wave-CAIPI SWI compared with conventional SWI and T2*-weighted gradient recalled-echo for routine clinical brain MRI at 3T. AJNR Am J Neuroradiol 40:2073\u20132080","journal-title":"AJNR Am J Neuroradiol"},{"key":"4724_CR70","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1754-9485.12929","volume":"63","author":"TB Shaw","year":"2019","unstructured":"Shaw TB, Jeffree RL, Thomas P, Goodman S, Debowski M, Lwin Z, Chua B (2019) Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. J Med Imaging Radiat Oncol 63:650\u2013656","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-020-04724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-020-04724-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-020-04724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:20:07Z","timestamp":1723065607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-020-04724-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4724"],"URL":"https:\/\/doi.org\/10.1007\/s00381-020-04724-1","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}